Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from CanSino Biologics, Inc. Class H ( (HK:6185) ) is now available.
CanSino Biologics Inc. has announced a proposal to use its reserves to offset accumulated losses amounting to approximately RMB1.45 billion as of December 31, 2024. This strategic move, approved by the Board of Directors and pending shareholder approval, aims to enhance the company’s ability to deliver investor returns and support its high-quality development by reducing its accumulated losses to zero.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, primarily engaged in the research, development, and commercialization of vaccine products. The company focuses on providing innovative vaccines to address global health challenges.
Average Trading Volume: 1,565,263
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.61B
Learn more about 6185 stock on TipRanks’ Stock Analysis page.